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Objective: Interleukin-1b (IL-1b) is involved in the up-regulation of matrix metalloproteinases (MMPs)
leading to cartilage degradation. Cannabinoids are anti-inﬂammatory and reduce joint damage in animal
models of arthritis. This study aimed to determine a mechanism whereby the synthetic cannabinoid
WIN-55,212-2 mesylate (WIN-55) may inhibit cartilage degradation.
Methods: Effects of WIN-55 were studied on IL-1b stimulated production of MMP-3 and -13 and their
inhibitors TIMP-1 and -2 in human chondrocytes. Chondrocytes were obtained from articular cartilage of
patients undergoing total knee replacement. Chondrocytes were grown in monolayer and 3D alginate
bead cultures. Real-time polymerase chain reaction (PCR) was used to determine the gene expression of
MMP-3, -13, TIMP-1 and -2 and Enzyme Linked Immunosorbent Assay (ELISA) to measure the amount of
MMP-3 and MMP-13 protein released into media. Immunocytochemistry was used to investigate the
expression of cannabinoid receptors in chondrocyte cultures.
Results: Treatment with WIN-55 alone or in combination with IL-1b, decreased or abolished MMP-3, -13,
TIMP-1 and -2 gene expression in human chondrocyte monolayer and alginate bead cultures in both a
concentration and time dependent manner. WIN-55 treatment alone, and in combination with IL-1b,
reduced MMP-3 and -13 protein production by chondrocytes cultured in alginate beads. Immunocyto-
chemistry demonstrated the expression of cannabinoid receptors in chondrocyte cultures.
Conclusion: Cannabinoid WIN-55 can reduce both basal and IL-1b stimulated gene and protein expres-
sion of MMP-3 and -13. However WIN-55 also decreased basal levels of TIMP-1 and -2 mRNA. These
actions of WIN-55 suggest a mechanism by which cannabinoids may act to prevent cartilage breakdown
in arthritis.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are debili-
tating joint diseases, and although they have a different aetiology a
key pathological feature of both is the loss of articular cartilage1.
Cannabis-basedmedicine Sativex has been shown to have analgesic
effects and to suppress disease activity in patients with RA2.: R.A.D. Bunning, Biomedical
Shefﬁeld Hallam University,
114-225-3066.
), j.m.wilkinson@shefﬁeld.ac.
rawford), C.Lemaitre@shu.ac.
b@exchange.shu.ac.uk (R.A.
s Research Society International. PCannabinoids also have anti-inﬂammatory effects and reduce joint
damage in animal models of arthritis3e5. In vitro studies have
shown that cannabinoids reduce cytokine production from RA ﬁ-
broblasts and the release of matrix metalloproteinases (MMPs)
from ﬁbroblast-like synovial cells6e8. Cannabinoids also have direct
effects on cartilage extracellular matrix (ECM) breakdown;
reducing interleukin 1 (IL-1) induced proteoglycan and collagen
degradation in bovine cartilage9. There is thus increasing evidence
to suggest that cannabinoids have chondroprotective effects and
may be of value in the treatment of arthritis10.
During OA and RA there is a shift in the equilibrium between
catabolic and anabolic activities1. As a result the breakdown of
collagen and proteoglycans may exceed the rate of synthesis of new
matrix molecules resulting in cartilage degradation. Another
contributing factor in cartilage breakdown in OA and RA is anublished by Elsevier Ltd. All rights reserved.
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necrosis factor (TNF) produced by the articular chondrocytes or
cells of the synovium11. This results in an increase in MMPs
particularly MMP-3 and MMP-13, which are expressed in RA and
OA cartilage and synovial tissue12e20, which is not accompanied by
an increase in their tissue inhibitors of matrix metalloproteinases
(TIMPs)21,22 resulting in a net increase in MMPs. MMP inhibition
has been proposed as a possible mechanism to prevent breakdown
of cartilage tissue in arthritis, provided the necessary functional
speciﬁcity can be achieved23.
To investigate further the potential of cannabinoids to regulate
cartilage breakdownwe have studied the effects of synthetic canna-
binoid WIN-55,212-2 mesylate (WIN-55) on basal and IL-1b stimu-
lated MMP-3, -13, TIMP-1 and -2 expression in human articular
chondrocytes from human OA cartilage tissue in monolayer and 3D
alginate bead culture. WIN-55 is an agonist at the classical cannabi-
noid receptors, cannabinoid receptor 1 and 2 (CB1 and2), but also has
been shown to activate other receptors including peroxisome pro-
liferator activated receptors alpha and gamma (PPARa and g)24e26.
Thus the expression of these receptors in cultured OA chondrocytes
was determined to identify potential targets of WIN-55.
Materials and methods
Human cartilage tissue
Human chondrocytes were obtained from articular cartilage
(n ¼ 9) removed from patients with symptomatic OA at the time of
total knee replacement (Supplementary Table I). Cartilage was
obtained under the National Research Ethics Service approval held
by the Shefﬁeld Musculoskeletal Biobank. All patients provided
written, informed consent prior to participation. Cartilage blocks
were taken from each anatomic compartment within the knee
(n ¼ 6e7) (medial and lateral tibio-femoral and patello-femoral
compartments). Cartilage tissue was graded macroscopically 0e4
using the Outerbridge classiﬁcation27. Chondrocytes were isolated
from grade 0 (n ¼ 3), grade 2 (n ¼ 6) and grade 3 (n ¼ 5) cartilage
tissue as representative of non-degenerate, low degenerate and
intermediate degenerate cartilage tissue. Cartilage from grade 4
severe degenerate tissue was not used in the study as the cell yield
obtained was not sufﬁcient.
Isolation of human chondrocytes
Cartilage tissue was digested in 0.25% trypsin (SigmaeAldrich,
Poole, UK) at 37C for 30 min followed by digestion in 3 mg/ml
collagenase type I (SigmaeAldrich, Poole UK) in Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM)/F-12 (1:1) (Gibco, Paisley, UK) sup-
plemented with 10% heat-inactivated foetal bovine serum (FBS)
(Gibco, Paisley, UK), 2 mM glutamine (Gibco, Paisley, UK), 100 U/ml
penicillin, 100 mg/ml streptomycin (Gibco, Paisley, UK), 2.5 mg/ml
amphotericin B (SigmaeAldrich, Poole, UK), and 50 mg/ml ascorbic
acid (SigmaeAldrich, Poole, UK) (complete media), at 37C for 16 h.
Cells were passed through a 70 mm cell strainer and washed twice
in DMEM/F12 supplemented with 2 mM glutamine, 100 U/ml
penicillin, 100 mg/ml, streptomycin, 2.5 mg/ml amphotericin B and
50 mg/ml ascorbic acid (serum free media). Cells were counted and
the viability checked using trypan blue staining. Chondrocytes
were cultured in monolayer in complete media in a humidiﬁed
atmosphere of 5% CO2 at 37C and harvested at passage 2.
Monolayer culture
Chondrocytes harvested at passage 2were seeded at a cell density
of 1  106 cells/well in a six well plate and maintained in completemedia in a humidiﬁed atmosphere of 5% CO2 at 37C for 24 h prior to
treatment to allow cells to adhere to the cell culture plate.
Alginate bead culture
When cultured in monolayer, chondrocytes dedifferentiate into
ﬁbroblast like cells28e30, therefore alginate beads were used to
redifferentiate the chondrocytes to their native phenotype. Chon-
drocytes harvested at passage 2 were encapsulated in alginate
beads at a cell density of 2  106 cells/ml, as previously described31.
Alginate beads were cultured in complete media in a humidiﬁed
atmosphere of 5% CO2 at 37C and the media changed every other
day. Chondrocytes were redifferentiated in alginate beads for 4
weeks prior to treatment.
Cytotoxicity studies
The CellTiter 96 AQueous One Solution Cell Proliferation Assay
(MTS) (Promega, Southampton, UK) was used to determine the
effects of 10 mM WIN-55 on the cell viability of human chon-
drocytes according to the manufacturer’s instructions.
Cannabinoid WIN-55 and IL-1b treatments
Prior to stimulation complete media was removed, cells washed
with serum free media and serum free media containing 500 mg/ml
bovine serum albumin (BSA) (SigmaeAldrich, Poole, UK) added.
Chondrocytes cultured in monolayer were unstimulated or stimu-
latedwith 10 ng/ml IL-1b (Peprotech, London, UK)with andwithout
1 mM, 2.5 mM, 5 mM, 7.5 mM and 10 mM WIN-55 (SigmaeAldrich,
Poole, UK) for 48 h at 37C. Chondrocytes inmonolayerwere treated
with 10 mM WIN-55 for 3, 6, 24 and 48 h at 37C. Chondrocytes
cultured in alginate beads were unstimulated or stimulated with
10 ng/ml IL-1bwith andwithout 10 mMWIN-55. Dimethyl sulfoxide
(DMSO) (SigmaeAldrich, Poole, UK) was used as a vehicle control at
0.1% (equivalent to that present in 10 mMWIN-55).
MMP-3 and -13 Enzyme Linked Immunosorbent Assays (ELISAs)
ELISAs (R&D Systems, Abingdon, UK) were used according to the
manufacturer’s instructions to measure pro and active MMP-3
protein expression (ng/ml) and pro MMP-13 protein expression
(pg/ml) in alginate bead conditioned culture media following
treatment with 10 mM WIN-55 with and without 10 ng/ml IL-1b
stimulation for 48 h.
RNA extraction from monolayers
For each of the three patient samples obtained fromOuterbridge
grade 0, 2 and 3 (n ¼ 9), patient samples were tested in triplicate.
Following treatments, media was removed, cells washed in 1xPBS
and RNA extracted in 1ml of TRIzol reagent (Invitrogen, Paisley, UK)
following the manufacturer’s instructions. RNAwas resuspended in
14 ml sterile deionised water.
RNA extraction from alginate beads
For each of the three patient samples obtained fromOuterbridge
grade 0, 2 and 3 (n ¼ 9), patient samples were tested in triplicate.
RNA was extracted from alginate beads using two beads per
extraction as described previously31. The resulting RNA was then
resuspended in 100 ml of sterile deionised water and the RNA was
puriﬁed using RNeasy clean up columns (Qiagen, Crawley, UK) ac-
cording to the manufacturer’s instructions and RNA eluted in 14 ml
of sterile deionised water.
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cDNA was formed as described previously31. Real-time PCR was
used to investigate MMP-3, -13, TIMP-1, and -2 gene expression
using Applied Biosystems Taqman Gene Expression Assays (Table I).
The reactions were performed for 40 cycles using Taqman Fast
Universal PCR Master Mix (Applied Biosystems, Paisley, UK) on an
ABI StepOnePlus real-time PCR machine (Applied Biosystems,
Paisley, UK). The data were collected and the fold changes in gene
expression analysed using the 2DDCt method32. Gene expression
was normalised to housekeeping genes GAPDH and 18S together
with untreated controls.Cannabinoid receptor expression in OA chondrocytes
Chondrocytes isolated from four patient samples of grade 2e3
cartilage at passage 2 were plated at a density of 1  105 cells in
eight well chamber slides and allowed to adhere overnight.
Chondrocytes were ﬁxed in 4% formalin and endogenous peroxi-
dases were quenched. Following 0.01% chymotrypsin antigen
retrieval at 37C for 20 min cells were blocked in 25% v/v goat
serum/BSA. Cells were incubatedwith rabbit polyclonal antibodies
(Abcam) overnight at 4C against CB1 (1/100), CB2 (1/50), PPARa
(1/150) and PPARg (1/50). A rabbit isotype IgG antibody (Abcam)
was used as negative control. Following washing cells were incu-
bated with biotinylated goat anti-rabbit secondary antibody (1/
300: Abcam) and binding detected using streptavidinebio-
tinylated horseradish peroxide complex (Vector Laboratories,
Peterborough, UK) with 3,30-diaminobenzidine tetrahydro-
chloride substrate (SigmaeAldrich). Cells were counterstained
using Mayer’s Haematoxylin (Leica Microsystems, Milton Keynes,
UK) dehydrated, cleared and mounted in Pertex (Leica Micro-
systems). Immunopositivity was visualised and images captured
using an Olympus BX60 microscope and QCapture Pro v8.0 soft-
ware (MediaCybernetics, Marlow, UK).Statistical analysis
Data was shown to be non-parametric via a ShapiroeWilk test
hence statistical signiﬁcance between DMSO vehicle control and
treatment groups was determined using the non-parametric
Kruskall-Wallis multiple comparisons test and Conover-Inman
post hoc test; P < 0.05 was considered statistically signiﬁcant for
real-time PCR and ELISA analysis. All statistical analysis was per-
formed using StatsDirect. All data analysis was performed using
individual replicates for each treatment group.Results
Cytotoxicity studies
Cytotoxicity studies showed that WIN-55 was not toxic to
chondrocytes at the concentrations used (Data not shown).Table I
Taqman gene expression assay IDs
Taqman gene expression assay Assay ID
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Hs9999905_m1
18S Hs99999901_s1
MMP-3 Hs00968305_m1
MMP-13 Hs00233992_m1
TIMP-1 Hs00171558_m1
TIMP-2 Hs00234278_m1Time-course and concentration dependent effects of WIN-55 on
MMP-3, MMP-13, TIMP-1 and TIMP-2 gene expression in monolayer
Chondrocytes were treated with WIN-55 (10 mM) for 3, 6, 24
and 48 h to determine the time point at which a maximum
decrease in gene expression was observed. MMP-3, -13, TIMP-1 and
-2 gene expression was decreased in a time-dependent manner, the
largest decrease was observed at 48 h [Supplementary Fig. 1(AeD)];
therefore this incubation time was used for all subsequent treat-
ments. Gene expression of MMP-3, -13, TIMP-1 and -2 was
decreased in a WIN-55 concentration dependent manner both with
and without IL-1b (10 ng/ml) stimulation [Supplementary Fig. 2(Ae
D)]. A signiﬁcant decrease in gene expression was observed at
concentrations 2.5 mM WIN-55 compared to DMSO (0.1%) vehicle
controls [Supplementary Fig. 2(AeD)]. WIN-55 was used at 10 mM
in all following treatments, as this was the maximal inhibitory non-
toxic concentration.Effects of DMSO in monolayer and alginate bead culture
No differences in gene or protein expression were observed
between untreated cells compared to cells treated with 0.1%
DMSO and 10 ng/ml IL-1b treatment in combination with 0.1%
DMSO compared to IL-1b treatment alone (Data not shown).
Therefore 10 ng/ml IL-1b in combination with 0.1% DMSO and
0.1% DMSO controls were used for all real-time PCR and ELISA
analysis.Effect of WIN-55 on IL-1b induced MMP-3 and MMP-13 gene
expression in monolayer
In order to determine the effects of WIN-55 on MMPs in the
presence of the inﬂammatory cytokine IL-1b, real-time PCR was
used to measure the gene expression of MMP-3 and -13 in
chondrocytes obtained from macroscopically graded OA cartilage.
For this purpose chondrocytes were stimulated with IL-1b to
induce MMP expression and co-treated with WIN-55. The effects
of WIN-55 alone were also investigated. IL-1b stimulation signif-
icantly induced MMP-3 gene expression in chondrocytes isolated
from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001)
cartilage and MMP-13 in chondrocytes isolated from grade
0 (P < 0.0001), grade 2 (P ¼ 0.02) and grade 3 cartilage
(P < 0.0001) compared to DMSO vehicle control [Fig. 1(AeF)].
Treatment with WIN-55 in combination with IL-1b signiﬁcantly
reduced MMP-3 and -13 gene expression in chondrocytes derived
from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001)
cartilage compared to IL-1b stimulation alone [Fig. 1(AeF)]. WIN-
55 treatment in combination with IL-1b also signiﬁcantly reduced
MMP-3 gene expression in chondrocytes isolated from grade
0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage and
MMP-13 gene expression in chondrocytes isolated from grade
0 (P < 0.0001), grade 2 (P ¼ 0.01) and grade 3 (P < 0.0001)
compared to DMSO vehicle control [Fig. 1(AeF)]. WIN-55 treat-
ment alone signiﬁcantly reduced MMP-3 gene expression in grade
0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage derived
chondrocytes below basal levels compared to DMSO vehicle con-
trol [Fig. 1(AeC)]. WIN-55 treatment alone also signiﬁcantly
decreased MMP-13 gene expression in grade 0 (P ¼ 0.002) and 3
(P < 0.0001) cartilage derived chondrocytes compared to DMSO
control [Figs. 1(D) and 1(F)]. MMP-13 was only expressed in two
samples in chondrocytes isolated from grade 2 cartilage following
WIN-55 treatment therefore statistical analysis could not be per-
formed [Fig. 1(E)].
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Fig. 1. AeC. The effect of WIN-55 on IL-1b induced MMP-3 gene expression in human OA chondrocytes isolated from grade 0, 2 and 3 cartilage and cultured in monolayer. DeF The
effect of WIN-55 on IL-1b induced MMP-13 gene expression in human OA chondrocytes isolated from grade 0, 2 and 3 cartilage and cultured in monolayer. Each point represents the
average of the repeats per patient. IL-1b (10 ng/ml) induced the gene expression of MMP-3 and -13. Following WIN-55 (10 mM) treatment in combination with IL-1b (10 ng/ml)
MMP-3 and -13 gene expression was decreased. WIN-55 (10 mM) alone decreased MMP-3 and -13 gene expression. ***P < 0.001, **P < 0.01 compared to DMSO (0.1 %) vehicle
control and þþþP < 0.001 compared to IL-1b (10 ng/ml) treatment. N ¼ 9 samples for each treatment group, obtained from three separate patient samples for each grade of tissue (0,
2 and 3) tested in triplicate.
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Fig. 2. AeC. The effect of WIN-55 on IL-1b induced MMP-3 gene expression in human chondrocytes isolated from grade 0, 2 and 3 cartilage and cultured in alginate beads. DeF. The
effect of WIN-55 on IL-1b induced MMP-13 gene expression in human OA chondrocytes isolated from grade 0, 2 and 3 cartilage and cultured in alginate beads. Each point represents
the average of the repeats per patient. IL-1b (10 ng/ml) induced the gene expression of MMP-3 and -13, following WIN-55 (10 mM) treatment in combination with IL-1b (10 ng/ml)
MMP-3 and -13 gene expression was decreased or abolished. WIN-55 (10 mM) alone decreased or abolished MMP-3 and -13 gene expression. *P < 0.05, *P < 0.01, ***P < 0.001
compared to DMSO vehicle control and þþþP < 0.001 compared to IL-1b treatment. N ¼ 9 samples for each treatment group, obtained from three separate patient samples for each
grade of tissue (0, 2 and 3) tested in triplicate.
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Fig. 3. AeC The effect of WIN-55 on TIMP-1 gene expression in human OA chondrocytes isolated from grade 0, 2 and 3 cartilage and cultured in monolayer. DeF. The effect of WIN-
55 on TIMP-2 gene expression in human OA chondrocytes isolated from grade 0, 2 and 3 cartilages and cultured in monolayer. Each point represents the average of the repeats per
patient. IL-1b (10 ng/ml) had no effect on TIMP-1 and -2 gene expression. WIN-55 treatment (10 mM) both alone and in combination with IL-1b (10 ng/ml) reduced TIMP-1 and -2
gene expression. ***P < 0.001 compared to DMSO vehicle control and þþþP < 0.001 compared to IL-1b treatment. N ¼ 9 samples for each treatment group, obtained from 3 separate
patient samples for each grade of tissue (0, 2 and 3) tested in triplicate.
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expression on chondrocytes cultured in alginate beads
The effects of WIN-55 on IL-1b induced MMP-3 and -13 gene
expression were determined in chondrocytes cultured in alginatebeads in order to determine gene expression in chondrocytes
following redifferentiation back to their native phenotype. IL-1b
stimulation signiﬁcantly induced MMP-3 gene expression in
chondrocytes from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3
(P < 0.0001) cartilage and MMP-13 gene expression in grade
S.L. Dunn et al. / Osteoarthritis and Cartilage 22 (2014) 133e144 1390 (P ¼ 0.018), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage derived
chondrocytes compared to DMSO vehicle control [Fig. 2(AeF)].
SimilarlyWIN-55 treatment in combinationwith IL-1b signiﬁcantly
reduced MMP-3 gene expression in grade 0 (P < 0.0001), 2
(P < 0.0001) and 3 (P< 0.0001) cartilage derived chondrocytes and
MMP-13 gene expression in grade 0 (P< 0.0001) and 3 (P< 0.0001)
cartilage derived chondrocytes compared to IL-1b stimulationA
B
C
Fig. 4. AeC. The effect of WIN-55 on TIMP-1 gene expression in human OA chondrocytes iso
WIN-55 on TIMP-2 gene expression in OA human chondrocytes isolated from grade 0, 2 an
repeats per patient. IL-1b (10 ng/ml) stimulation increased TIMP-1 gene expression and decre
and in combination with IL-1b (10 ng/ml) reduced TIMP-1 and -2 gene expression. *P < 0.05,
to IL-1b treatment. N ¼ 9 samples for each treatment group, obtained from 3 separate patialone [Fig. 2(AeD) and (F)]. MMP-13 was not expressed in chon-
drocytes from grade 2 cartilage treated with IL-1b in combination
withWIN-55 [Fig. 2(E)]. WIN-55 treatment in combinationwith IL-
1b signiﬁcantly reduced MMP-3 (P¼ 0.03) and -13 (P¼ 0.003) gene
expression in chondrocytes from grade 0 cartilage compared to
DMSO vehicle control [Fig. 2(A) and (D)]. WIN-55 treatment in
combination with IL-1b reduced MMP-3 gene expression inD
E
F
lated from grade 0, 2 and 3 cartilages and cultured in alginate beads. DeF. The effect of
d 3 cartilages and cultured in alginate beads. Each point represents the average of the
ased TIMP-2 gene expression below basal levels. WIN-55 treatment (10 mM) both alone
**P < 0.01, ***P < 0.001 compared to DMSO vehicle control and þþþP < 0.001 compared
ent samples for each grade of tissue (0, 2 and 3) tested in triplicate.
Table II
The effect of WIN-55 on pro and active MMP-3 and pro-MMP-13 protein release into
culture media from grade 3 OA chondrocytes cultured in alginate beads
Treatment (48 h) MMP-3
(ng/alginate bead)
MMP-13
(pg/alginate bead)
DMSO (0.1%) 1.4 (0.0659) 327.5 (1.6407)
IL-1b
(10 ng/ml) þ DMSO (0.1%)
38.4*** (0.5092) 1,092.0* (16.8345)
WIN-55
(10 mM) þ IL-1b (10 ng/ml)
1.4þþþ (0.0178) 219.4þþþ (1.2038)
WIN-55 (10 mM) 0.2* (0.0051) 270.7 (3.8866)
Results are expressed as mean and 95% conﬁdence interval; *P < 0.05,
***P < 0.001,compared to DMSO vehicle control and þþþP < 0.001 compared to IL-
1b treatment alone.
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(P ¼ 0.58) and -13 (P ¼ 0.11) gene expression in chondrocytes
from grade 3 cartilage compared to DMSO vehicle control; however
this was not signiﬁcant [Fig. 2(B), (C) and (F)]. There was no sig-
niﬁcant difference from basal levels of MMP-3 gene expression in
grade 0 (P ¼ 0.052) and 3 (P ¼ 0.16) cartilage derived chondrocytes
when treated with WIN-55 alone [Fig. 2(A and C)]. MMP-3 was not
expressed in grade 2 cartilage chondrocytes treated with WIN-55
alone [Fig. 2(B)]. MMP-13 was abolished in chondrocytes from
grade 2 and 3 cartilage treated with WIN-55 alone [Fig. 2(D-F)].
Effects of WIN-55 on IL-1b induced TIMP-1 and TIMP-2 gene
expression in monolayer
In order to determine the effects of WIN-55 on the inhibitors of
MMP-3 and -13 the gene expression of TIMP-1 and -2 was inves-
tigated followingWIN-55 treatment both alone and in combination
with IL-1b. IL-1b stimulation had no signiﬁcant effect on TIMP-1
gene expression in chondrocytes derived from grade 0 (P ¼ 0.75),
2 (P ¼ 0.60) and 3 (P ¼ 0.12) cartilage or TIMP-2 gene expression in
chondrocytes isolated from grade 0 (P ¼ 0.77), 2 (P ¼ 0.49) and 3
(P ¼ 0.98) cartilage [Fig. 3(AeF)]. However, WIN-55 treatment in
combinationwith IL-1b resulted in a signiﬁcant decrease in TIMP-1
gene expression compared to DMSO vehicle control and IL-1b
stimulated chondrocytes derived from grade 0 (P < 0.0001), 2
(P< 0.0001) and 3 (P¼ 0.001) cartilage [Fig. 3(AeC)]. WIN-55 alone
also signiﬁcantly reduced TIMP-1 gene expression in chondrocytes
derived from grade 0 (P < 0.0001) and 2 (P < 0.0001) cartilage
below basal levels [Fig. 3(A) and (B)]. TIMP-1 gene expression was
decreased in chondrocytes derived from grade 3 cartilage following
WIN-55 treatment however this was not signiﬁcant (P ¼ 0.11)
[Fig. 3(C)]. TIMP-2 gene expression was signiﬁcantly reduced
following WIN-55 treatment in combination with IL-1b compared
to DMSO vehicle control and IL-1b stimulation in chondrocytes
derived from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3
(P < 0.0001) cartilage [Fig. 3(DeF)]. WIN-55 alone signiﬁcantly
reduced the gene expression of TIMP-2 below basal levels in
chondrocytes isolated from grade 0 (P< 0.0001), 2 (P< 0.0001) and
3 (P < 0.0001) cartilage [Fig. 3(DeF)].
Effects of WIN-55 on IL-1b induced TIMP-1 and TIMP-2 gene
expression on chondrocytes cultured in alginate beads
TIMP-1 gene expression was signiﬁcantly increased in grade 2
(P < 0.0009) and 3 cartilage derived chondrocytes (P ¼ 0.02)
following IL-1b stimulation [Fig. 4(B) and (C)] but not in grade
0 (P ¼ 0.24) cartilage chondrocytes compared to DMSO vehicle
control [Fig. 4(A)]. In contrast TIMP-2 gene expression was signif-
icantly decreased following IL-1b treatment in chondrocytes
extracted from grade 0 (P¼ 0.009), 2 (P¼ 0.001) and 3 (P< 0.0001)
cartilage compared to DMSO vehicle control [Fig. 4(DeF)]. WIN-55
treatment in combination with IL-1b resulted in a signiﬁcant
decrease in TIMP-1 gene expression in chondrocytes derived from
grades 0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001), cartilage
and TIMP-2 gene expression in chondrocytes isolated from grades
0 (P < 0.0001), 2 (P < 0.0001), and 3 (P ¼ 0.0007), cartilage
compared to IL-1b stimulation [Fig. 4(AeF)]. WIN-55 treatment in
combination with IL-1b also resulted in a signiﬁcant decrease in
TIMP-1 gene expression in chondrocytes derived from grades
0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001), cartilage and
TIMP-2 gene expression in chondrocytes isolated from grades
0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001) cartilage
compared to DMSO control [Fig. 4(AeF)]. WIN-55 treatment alone
signiﬁcantly reduced both TIMP-1 gene expression in chondrocytes
derived from grade 0 (P ¼ 0.0005), 2 (P < 0.0001) and 3(P ¼ 0.0003) cartilage below basal levels [Fig. 4(AeC)]. WIN-55
treatment alone signiﬁcantly reduced both TIMP-2 gene expres-
sion in chondrocytes derived from grade 0 (P < 0.0001), 2
(P < 0.0001) and 3 (P < 0.0001) cartilage below basal levels
[Fig. 4(DeF)].
The effects of WIN-55 on MMP-3 and -13 protein expression
In order to determine whether WIN-55 also inhibited MMP-3
and -13 expression at the protein level, pro and active MMP-3
and pro MMP-13 were measured in culture media using ELISA.
Culture media obtained from chondrocytes isolated from grade 3
cartilage which had been cultured in alginate beads were used, as
these demonstrated clear gene expression effects. Following stim-
ulation of chondrocytes with IL-1b there was a signiﬁcant increase
in MMP-3 (P < 0.0001) and -13 (P ¼ 0.046) protein release into the
media (Table II). Treatment of chondrocytes with WIN-55 in com-
bination with IL-1b signiﬁcantly reduced both MMP-3 (P ¼ 0.0007)
and -13 (P ¼ 0.0005) protein compared to IL-1b treatment alone
(Table II). WIN-55 treatment alone signiﬁcantly reduced MMP-3
protein release to below basal levels (P ¼ 0.04) and MMP-13
(P ¼ 0.38) protein levels remained at basal level (Table II).
Cannabinoid receptor expression in OA chondrocytes
To identify the expression of cannabinoid receptors CB1, CB2,
PPARa and PPARg in chondrocytes cultured in monolayer immu-
nocytochemistry was used. Here we observed the expression of
CB1, CB2, PPARa and g [Fig. 5]. PPARa and g expression was local-
ised to the cytoplasm and nucleus [Fig. 5].
Discussion
Cartilage degradation is a pathological feature of both OA and
RA1. The inﬂammatory cytokine IL-1 plays a key role in cartilage
destruction and stimulates increased production of MMPs by
chondrocytes, resulting in the breakdown of collagen and proteo-
glycan33. Here, we have shown that treatment of articular chon-
drocytes from human OA cartilage with cannabinoid WIN-55
reduces the gene and protein expression of MMP-3 and MMP-13 in
the presence of IL-1b, suggesting that cannabinoids may have po-
tential in terms of arthritis therapy. In additionwe have shown that
WIN-55 signiﬁcantly reduces the gene expression of TIMP-1 and
TIMP-2 to below basal levels.
In this study we have used both monolayer and a 3D culture
system for culture of chondrocytes. Chondrocytes that have been
isolated from articular cartilage dedifferentiate in monolayer cul-
ture changing their matrix synthesis, with a decrease in type II
collagen and aggrecan, developing a ﬁbroblast like phenotype and
an increase in collagen type I28e30. Dedifferentiation can be
Fig. 5. Cannabinoid receptor expression in OA chondrocytes cultured in monolayer. Representative photomicrographs of immunocytochemistry of (A) CB1, (B) CB2, (C) PPARa, (D)
PPARg, (E) IgG control (10 mg) (n ¼ 4 cultures).
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preservedwhen cultured in a 3D system such as alginate beads34. In
this study, chondrocytes were treated with IL-1b to mimic in-
ﬂammatory processes in an in vitro model of OA35.
Synthetic cannabinoids WIN-55 and HU-210 reduce IL-1a
induced proteoglycan and collagen degradation in bovine nasal
cartilage tissue suggesting a chondroprotective effect of these
compounds9. Here, we have shown a possible mechanism bywhich
WIN-55may prevent IL-1b induced ECM breakdown in OA cartilage
tissue via preventing the expression of MMPs. We have demon-
strated that chondrocytes from different grades of OA cartilage
modulate MMP-3 and MMP-13 expression in response to WIN-55
with and without IL-1b stimulation. These ﬁndings together with
others, suggest that cannabinoids may be of importance in the
treatment of arthritis3e5,7,8,36. Selvi et al. 2008 demonstrated that
WIN-55 and CP55,940 inhibit IL-1b induced secretion of IL-6 and IL-
8 in RA ﬁbroblast like synovial cells, suggesting an anti-
inﬂammatory activity of cannabinoids7. In another study non-psychoactive cannabinoid ajulemic acid (AJA) reduced MMP-1,
MMP-3 and MMP-9 release from ﬁbroblast like synovial cells
stimulated with IL-1a and TNFa8. In vivo, AJA has also been shown
to reduce the severity of adjuvant-induced arthritis4 and other non-
psychoactive cannabinoids, cannabidiol (CBD) and HU-320 reduced
inﬂammation and joint damage in murine collagen-induced
arthritis3,5.
The effects of WIN-55 on articular chondrocytes did not appear
to be inﬂuenced by the grade of the cartilage they were isolated
from when cultured in monolayer. Chondrocytes cultured in
monolayer express MMP-3 and MMP-13 at very low levels
followingWIN-55 treatment. However when comparing the effects
of WIN-55 in monolayer to alginate bead culture, a greater inhibi-
tory effect on MMP-3 and MMP-13 gene expression was seen in
alginate bead cultured chondrocytes. Interestingly a biphasic
expression pattern of MMP-3 and MMP-13 in response to WIN-55
was observed. MMP-3 was expressed in grade 0 and grade 3
cartilage derived chondrocytes and abolished in grade 2 cartilage
S.L. Dunn et al. / Osteoarthritis and Cartilage 22 (2014) 133e144142chondrocytes and MMP-13 was abolished in chondrocytes from all
grades of cartilage when cultured in alginate beads. These varying
responses to WIN-55 treatment in alginate bead culture may
indicate that the expression of MMPs may be differentially regu-
lated depending on the grade and extent of cartilage degradation
and the culture method utilised. Studies have shown that cartilage
tissue derived from different OA grades or normal aged cartilage
may inﬂuence the response of the chondrocytes to different
treatments37e42. Interestingly biphasic effects have also been seen
with other cannabinoids namely AJA43.
During OA there is thought to be an imbalance between MMP
and TIMP expression which in part contributes to cartilage break-
down21. We have shown that WIN-55 inhibits expression of both
destructive MMPs and protective TIMPs involved in the patho-
genesis of OA, indicating that inhibition may occur via a signalling
pathway, which regulates both at the transcription level. Human
MMPs and TIMPs share a common activating protein 1 (AP-1) site in
their promoters which regulates their transcription44. WIN-55 may
have a differential effect on AP-1 activation via peroxisome pro-
liferator activated receptors (PPARs). WIN-55 has been shown to
activate AP-1 via PPARa. In addition AP-1 may be involved in the
activation of interferon b (IFNb)45. Production of IFNbmay result in
reduced levels of MMPs and TIMPs. IFNb reduced MMP-1, -3 and
TIMP-1 in ﬁbroblast-like synovial cells both with and without IL-1b
stimulation and synovial tissue from patients with RA, treated with
IFNb, showed reduced levels of MMP-1 and TIMP-146. Furthermore
IFNb has been shown to have anti-inﬂammatory properties in the
treatment of arthritis47e49. Conversely PPARg agonists have been
shown to reduce IL-1b induced MMP-1 expression in human sy-
novial ﬁbroblasts via inhibiting DNA binding of AP-150. WIN-55 also
binds to PPARg so could also act in this way51. The biological ac-
tivities of cannabinoids and the signal transduction pathways they
induce or inhibit need to be further investigated in OA. Since TIMP-
1 and -2 are decreased by WIN-55 in human OA chondrocytes it is
unclear whether there is a change in MMP and TIMP balance
following cannabinoid treatment. However the inhibitory effect of
WIN-55 on MMP-3 and -13 expression would indicate a possible
role of cannabinoids in suppressing IL-1b induced ECM degradation
by MMPs.
We have observed the expression of both classical cannabinoid
receptors CB1 and CB2 in human chondrocytes from OA cartilage at
passage 2. CB1 and CB2 have previously been shown to be
expressed at similar levels both at the protein and RNA level in
synovia of patients with OA and RA and their expression is thought
to play a role in the pathology of joint disease52. PPARa and g were
also expressed in OA chondrocytes at passage 2 and their expres-
sion appears to be both cytoplasmic and nuclear. PPARs are nuclear
receptors however studies have also shown that the localisation of
PPARa receptors in chondrocytes is also cytoplasmic53. WIN-55
activates CB1 and CB2 with Kis of 1.89e123 nM and 0.28e
16.2 nM respectively24. In addition, WIN-55 has also been shown to
activate PPARa and g25,26. Targeting PPARs using both speciﬁc and
cannabinoid agonists for the treatment of OA and RA has been re-
ported previously8,26,36,50,54e56. The observed effects of WIN-55 on
MMP and TIMP expression may be mediated by one or more of
these receptors or by receptors as yet unknown.
In conclusion, in human OA chondrocytes, the synthetic
cannabinoid WIN-55 inhibits the expression of matrix degrading
enzymes MMP-3 and -13 and their inhibitors TIMP-1 and -2 in the
presence or absence of IL-1b. This suggests a possible mechanism
by which cannabinoids may act to prevent ECM breakdown in
arthritis. Cannabinoids could provide a dual role in the treatment of
arthritis as disease modifying agents in addition to having anti-
inﬂammatory properties10. Although there is increasing evidence
to suggest that cannabinoids may be of therapeutic value in thetreatment of arthritis, further studies into the receptors and sig-
nalling pathways involved in the actions of cannabinoids need to be
investigated in order to elucidate their effects on catabolic and
anabolic mediators in both normal and arthritic cartilage.
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